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L E T T E R  T O  T H E  E D I T O R
Novel coronavirus (SARS-CoV-2) infection in a patient with 
multivisceral transplant
To the Editor,
Coronavirus disease 2019 (COVID-19) pandemic has become 
one of the most challenging episodes in the history of modern public 
health, with particular emphasis in high-risk population.1 However, 
the evidence regarding their response to the severe acute respira-
tory	 syndrome	coronavirus	2	 (SARS-CoV-2),	 the	agent	 responsible	
for COVID-19 is scant.2 Herein, we present the clinical and thera-
peutic	course	of	a	SARS-CoV-2	infection	in	a	patient	with	multivis-
ceral transplant and a recent tuberculosis infection.
A	 31-year-old	male	 that	 on	March	 2003	was	 diagnosed	with	
volvulus and required an extensive intestinal resection. On June 
2006,	 he	 received	 an	 isolated	 intestinal	 graft.	 At	 the	 age	 of	 29,	
he was diagnosed with chronic rejection, and 4 months later (July 
2018), he received a multivisceral transplant. On December 2018, 
patient was diagnosed with disseminated tuberculosis and quadru-
ple antibiotic therapy was initiated. During 2019, he required occa-
sional hospital admissions to manage the mutifactorial respiratory 
problems.
Patient's	 history	 of	 SARS-CoV-2	 infection	 is	 summarized	 in	
Figure	1.	On	March	9	(day	−12),	patient	went	to	the	outpatient	clinic	
with mild fever, cough, runny nose, and diarrhea. Notable labora-
tory results are shown in Table 1. Pharyngeal adenovirus infection 
was diagnosed, with C-reactive-protein (CRP) and white blood cells 
(WBC)	above	normal	range.	On	March	13,	abdominal	pain	got	worse	
and blood in stool appeared; therefore, he was admitted for hos-
pital monitoring. Vital signs were between normal ranges during 
the	whole	hospitalization	period.	RT-PCR	 testing	was	negative	 for	
both	adenovirus	(pharyngeal	smear	and	peripheral	blood)	and	SARS-
CoV-2	 (nasopharyngeal	 swab).	 As	 seen	 in	 the	 previous	 laboratory	
test, WBC, platelets, and CRP values were above normal range.
On	 day	 −6,	 thorax-Rx	 showed	 residual	 right	 pleural	 effusion,	
similar	 to	 previous	 study	 (March	 2019).	 No	 signs	 compatible	with	
COVID-19 lung infection were observed. Considering that patient 
still presented moderate abdominal pain and diarrhea, an abdominal 
ultrasound test was performed, revealing ileitis and adenitis.
Considering COVID-19 epidemiological environment and patient 
health	 status	 on	March	 24	 (Day	 0),	 a	 nasopharyngeal	 sample	was	
taken	and	patient	was	discharged	from	hospital.	Nevertheless,	SARS-
CoV-2 RT-PCR came back positive (Day 1). Hydroxychloroquine 
treatment was empirically started at that moment, and home mon-
itoring	 with	 consulting	 every	 2-3	 days	 was	 recommended.	 Along	
home isolation period, no respiratory symptoms were reported. 
Laboratory	 test	 results	 of	 days	 4,	 7,	 and	 11	 showed	WBC	 above	
normal	 range	 but	 normal	 lymphocytes	 count.	 Although	 elevated	
compared to reference values, CRP was notably lower than before 
COVID-19 diagnosis.
Platelet count and D-dimer values were also above normal 
range during days 4-11. Nonetheless, derived fibrinogen, pro-
thrombin, and cephalin time remain between normal range during 
that	 time	 lapse.	 It	 is	 important	 to	 emphasize	 that	 patient	 was	
already receiving anticoagulant prophylaxis with bemiparin due 
to chronic central vein thrombosis and because he was carrier 
of a central catheter. Renal function presented elevated levels 
of blood urea nitrogen (BUN) and lactate dehydrogenase (LDH) 
during the COVID-19 episode. However, estimated glomerular 
filtration rate and serum creatinine were in normal range. Both 
aspartate	 aminotransferase	 (AST)	 and	 alanine	 aminotransferase	
(ALT)	were	already	above	normal	values	during	 the	days	−12/-5	
and remain elevated at Day 11. Ferritin levels were between nor-
mal	range,	but	10	times	higher	compare	to	values	of	Day	−12.	At	
days	34	and	45,	patient	had	 two	negative	SARS-CoV-2	RT-PCR.	
Interestingly,	 we	 could	 not	 detect	 specific	 IgG/IgM	 antibodies	
against	 SARS-CoV-2	 in	 serum	 after	 recovery	 (Anti-S	 glycopro-
tein	 ELISA	 determination)	 nor	 virus	 specific	 CD4+/CD8+ T cells 
(IFN-γ	 production	 after	 in	 vitro	 stimulation	 with	 SARS-CoV-2	
peptides-flow cytometry determination). Patient was under tac-
rolimus administration along this episode, and despite physiolog-
ical variations, blood levels remain between the desired range of 
6-8 ng/mL (Table 1).
In	 this	 multivisceral	 transplant	 recipient	 with	 SARS-CoV-2	 in-
fection, gastrointestinal manifestations could be related to the al-
tered immunological status of the graft and should be taken into 
consideration in further cases.3 Whether the favorable outcome 
was due to patient low risk because of his age, hydroxychloroquine, 
anticoagulant, or immunosuppressant treatment (or a combination 
of all those factors) cannot be concluded.4,5 However, central role 
of	SARS-CoV-2	early	detection	and	treatment	cannot	be	ruled	out.	
Of note, the immunosuppressive regime used was higher than in 
other solid organ transplants and was not suspended nor diminished 
during COVID-19 episode.6 This fact could influence the patient T 
and B unresponsiveness against the virus; nevertheless, he achieved 
infection	 resolution	 without	 severe	 respiratory	 symptoms.	 More	
experience needs to be accumulated in order to conclude whether 
transplanted	 patients	 represent	 or	 not	 a	 group	 of	 risk	 for	 SARS-
CoV-2 infection and determine the best way to handle immunosup-
pression treatment.
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F I G U R E  1  COVID-19	episode	timeline.	Notable	events	from	12	days	before	COVID-19	diagnosis	and	until	45	days	after	that	moment	
are shown. Pharmacological treatments, patient symptoms, days on which laboratory samples were taken, imaging findings, and time of 
hospitalization	are	depicted.).	Abbreviations:	PS,	pharyngeal	smear;	PB	peripheral	blood;	NS,	nasopharyngeal	swab;	SARS-CoV-2,	severe	
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−12 Day −8 Day −5 Day 1 Day 4 Day 7 Day 11 Day 34
Day 
45
SARS-CoV-2 (−) (+) (−) (−)
Adenovirus (+) (−)
Virus/Bacteria/Parasites (−) (−)
Albumin	(g/dL) 2.9-5.2 4.3 4.4 4 4.5 4.8
CRP (mg/mL) 0-5 35.1 23.2 9,6 5.8 5.8 6.6 7.2 19.5
AST	(U/L) <40 56 44 43 42 46
ALT	(U/L) <35 75 64 67 80 94
Ferritin (ng/mL) 22-322 24 248 169 157
eGFR	(mL/min/1.73m2) >75 >90 >90 85 >90 >90 >90 88
BUN (mg/dL) 11-49 57 38 35 62 80
SCr (mg/dL) 0.7-1-3 0.98 0.85 1.01 1.03 1.07 1.11
LDH (U/L) 100-190 253 213 232 269
Prothrombin time (s) 11.9 12.7 12.5 11.9 11.9 11.5
Derived fibrinogen (mg/dL) 150-450 397 352 319 344 321 253
Cephalin time (s) 28.9 24.8 25.4 27.9 27.7 28.4
D-dimer (ng/mL) 0-500 2114 1803 1844 1440 2150
WBC (x103/uL) 3.9-10.2 11.36 11.41 10.41 12.41 11.05 12.38 9.42 9.0
Neutrophils (x103/uL) 1.5-7.70 5.67 6.02 5.3 5.6 4.7 5 4.08 4.19
Lymphocytes (x103/uL) 1.1-4.5 1.91 1.71 1.47 2.54 2.19 2.85 2.33 1.82
Monocytes	(x103/uL) 0.10-0.9 0.98 1 1.08 1.22 0.97 1.31 0.96 0.72
Eosinophils (x103/uL) 0.02-0.65 2.48 2.37 2.29 2.68 2.88 2.86 1.8 2.12
Platelets (x103/uL) 150-370 451 460 486 477 500 480 393 297




C3 (mg/dL) 75-135 131
C4 (mg/dL) 14-60 27.80
CD4+	SARS-CoV-2 (−)
CD8+	SARS-CoV-2 (−)
Tacrolimus (ng/mL) 6-8 4.3 13.9 9.3 3.2 7.2 7.6 7.5 8.6
Sirolimus (ng/mL) 6-8 10.3
Note:: Values unbold were above reference range. Flow cytometry experiments: lymphocytes were gated according to their forward and side 
characteristics. CD4 and CD8 cells were previously defined as CD3+CD45RA-7AAD-.
Abbreviations:	ALT,	alanine	aminotransferase;	AST,	aspartate	aminotransferase;	BUN,	blood	urea	nitrogen;	CRP,	C-reactive	protein;	eGFP,	estimated	
glomerular	filtration	rate	(based	on	CKD-EPI	creatinine);	LDH,	lactate	dehydrogenase;	SARS-CoV-2,	severe	acute	respiratory	syndrome	coronavirus	
2; Scr, serum creatinine; WBC, white blood cells.
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